Circulating acylcarnitine alterations in glaucoma: an exploratory study on systemic metabolic association

Abstract Glaucoma is a leading cause of irreversible blindness and has increasingly been linked to systemic metabolic alterations. In particular, mitochondrial dysfunction affecting lipid metabolism may contribute to disease pathophysiology. Acylcarnitines, intermediates of mitochondrial fatty acid oxidation, represent markers of systemic metabolic status and may reflect alterations in energy metabolism relevant to glaucoma. The gut microbiome may modulate host metabolism through microbial metabolites and immune-related pathways. In this exploratory cross-sectional study, shotgun metagenomic sequencing and targeted metabolomics were integrated to investigate differences in gut microbial composition and circulating acylcarnitine profiles between 16 glaucoma patients and 16 healthy controls. Analysis of the gut microbiome revealed no differences in alpha diversity or overall community composition between groups. However, species-level analysis identified limited differences, including increased relative abundance of Candidatus Pararuminococcus gallinarum in glaucoma (exploratory false discovery rate threshold, q ≤ 0.25), which did not remain below this threshold when age was included as a fixed effect. In contrast, the overall circulating acylcarnitine profile was significantly associated with age (PERMANOVA, R² = 0.078, p = 0.033) but not independently with glaucoma status (R² = 0.052, p = 0.126) in this decomposition. At the individual metabolite level, circulating acylcarnitine profiles showed several exploratory FDR-selected associations with glaucoma status (q ≤ 0.25, strongest for hexadecenoylcarnitine, q = 0.105), with predominantly medium- and long-chain acylcarnitines showing higher levels in glaucoma patients, a pattern which may be consistent with altered mitochondrial lipid metabolism. Integrative analyses showed only limited associations between microbial taxa and circulating acylcarnitines. These findings suggest changes in systemic metabolism rather than in the gut microbiome. Larger studies are needed to further elucidate potential interactions between host metabolism and the gut microbiome in glaucoma. Trial registration: ClinicalTrials.gov, TRN NCT02438111, Registration date 28. April 2015.

Authors

Institutions

Publication Details

Journal
BMC Microbiology
Published
2026-11-13
DOI
https://doi.org/10.1186/s12866-026-05917-5
Primary Topic
Glaucoma and retinal disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Circulating acylcarnitine alterations in glaucoma: an exploratory study on systemic metabolic association

Jan Darius Unterlauft, Martin Sebastian Zinkernagel, Déborah Mathis, Denise C. Zysset‐Burri et al.
BMC Microbiology
Glaucoma and retinal disorders
article

Circulating acylcarnitine alterations in glaucoma: an exploratory study on systemic metabolic association

Jan Darius Unterlauft, Martin Sebastian Zinkernagel, Déborah Mathis, Denise C. Zysset‐Burri, Carlo Rodolfo Largiadèr, Livia A. Spörri, Nina Eldridge, Gianna Haldimann
article en

Abstract

Abstract Glaucoma is a leading cause of irreversible blindness and has increasingly been linked to systemic metabolic alterations. In particular, mitochondrial dysfunction affecting lipid metabolism may contribute to disease pathophysiology. Acylcarnitines, intermediates of mitochondrial fatty acid oxidation, represent markers of systemic metabolic status and may reflect alterations in energy metabolism relevant to glaucoma. The gut microbiome may modulate host metabolism through microbial metabolites and immune-related pathways. In this exploratory cross-sectional study, shotgun metagenomic sequencing and targeted metabolomics were integrated to investigate differences in gut microbial composition and circulating acylcarnitine profiles between 16 glaucoma patients and 16 healthy controls. Analysis of the gut microbiome revealed no differences in alpha diversity or overall community composition between groups. However, species-level analysis identified limited differences, including increased relative abundance of Candidatus Pararuminococcus gallinarum in glaucoma (exploratory false discovery rate threshold, q ≤ 0.25), which did not remain below this threshold when age was included as a fixed effect. In contrast, the overall circulating acylcarnitine profile was significantly associated with age (PERMANOVA, R² = 0.078, p = 0.033) but not independently with glaucoma status (R² = 0.052, p = 0.126) in this decomposition. At the individual metabolite level, circulating acylcarnitine profiles showed several exploratory FDR-selected associations with glaucoma status (q ≤ 0.25, strongest for hexadecenoylcarnitine, q = 0.105), with predominantly medium- and long-chain acylcarnitines showing higher levels in glaucoma patients, a pattern which may be consistent with altered mitochondrial lipid metabolism. Integrative analyses showed only limited associations between microbial taxa and circulating acylcarnitines. These findings suggest changes in systemic metabolism rather than in the gut microbiome. Larger studies are needed to further elucidate potential interactions between host metabolism and the gut microbiome in glaucoma. Trial registration: ClinicalTrials.gov, TRN NCT02438111, Registration date 28. April 2015.

BMC Microbiology
University of Bern (CH), University Hospital of Bern (CH)
University of Bern
Good health and well-being
Glaucoma and retinal disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon